AKTX
Akari Therapeutics PlcCompany Information
- Company Name
- Akari Therapeutics Plc
- CIK
- CIK0001541157
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AKTX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- AKTX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-25
- Last sale
- —
- Shares purchased (TTM)
- 33,203
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-12-31
- Institutional shares owned
- 4,452,851
- Shares outstanding
- 841,602
- Ownership
- —
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 63.86%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
| Cash | - | 3 | 5 | 2 | - | 3 | 3 | 2 | - | - | - | ||||||
| Cash And Cash Equivalents At Carrying Value | 8 | 3 | 0 | - | 3 | 3 | 0 | 2 | 4 | 1 | 4 | ||||||
Assets Current | |||||||||||||||||
| Assets Current | 8 | 4 | 5 | 3 | 3 | 3 | 3 | 3 | 5 | 3 | 4 | ||||||
| Restricted Cash | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | ||||||
| Prepaid Expense Current | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | ||||||
| Other Assets Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Goodwill | - | - | 8 | 8 | 8 | 8 | 8 | - | - | - | - | ||||||
| Other Intangible Assets Net | 30 | 30 | 34 | 34 | 39 | 39 | 39 | - | - | - | - | ||||||
| Assets | 39 | 34 | 48 | 45 | 51 | 51 | 51 | 3 | 5 | 3 | 4 | ||||||
Liabilities And Stockholders Equity | |||||||||||||||||
| Accounts Payable Current | 9 | 9 | 9 | 11 | 12 | 13 | 12 | 5 | 5 | 3 | 2 | ||||||
Liabilities Current | |||||||||||||||||
| Accrued Liabilities Current | 4 | 3 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Liabilities Current | 14 | 13 | 12 | 16 | 17 | 21 | 20 | 9 | 9 | 6 | 5 | ||||||
| Convertible Debt | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | - | - | - | ||||||
| Notes Payable Current | - | 0 | 0 | 0 | 0 | 0 | 1 | - | - | - | - | ||||||
| Other Liabilities Current | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | ||||||
| Derivative Liabilities Noncurrent | - | - | 0 | 0 | - | - | - | - | - | - | - | ||||||
| Other Liabilities Noncurrent | - | - | 0 | 0 | 0 | 0 | 0 | - | - | - | - | ||||||
| Deferred Income Tax Liabilities Net | 6 | 6 | 7 | 7 | 8 | 8 | 8 | - | - | - | - | ||||||
| Liabilities | 20 | 20 | 20 | 23 | 25 | 29 | 28 | - | - | - | 5 | ||||||
| Common Stock Value | 0 | - | - | 7 | 7 | 6 | 5 | 2 | 2 | 2 | 1 | ||||||
| Additional Paid In Capital | 244 | 235 | 234 | 224 | 221 | 216 | 213 | 183 | 183 | 176 | 175 | ||||||
Stockholders Equity | |||||||||||||||||
| Stockholders Equity | 19 | 14 | 28 | 23 | 26 | 22 | 22 | -7 | -4 | -4 | -0 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -284 | -279 | -265 | -259 | -253 | -251 | -247 | -243 | -241 | -233 | -227 | ||||||
| Liabilities And Stockholders Equity | 39 | 34 | 48 | 45 | 51 | 51 | 51 | 3 | 5 | 3 | 4 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 55 | 10 | 10 | 4 | 4 | 3 | 3 | 1 | 1 | 1 | 1 | ||||||
| Common Stock Shares Issued | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAkari Therapeutics Plc (AKTX) — SEC Financial Statements & Analysis
Akari Therapeutics Plc (AKTX) is a pharmaceutical preparations company, incorporated in X0. Akari Therapeutics Plc trades on Nasdaq as: AKTX. Akari Therapeutics Plc (AKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Akari Therapeutics Plc carries a market cap of $18.35M, a P/E ratio of -0.59x, a P/B ratio of 0.99x, an enterprise value of $11.29M, and an EV/EBITDA multiple of -0.36x. On profitability, it posts a Return on Equity (ROE) of -140.09%, a Return on Assets (ROA) of -69.16%, and a Return on Invested Capital (ROIC) of -175.85%. Per share, it reports EPS of $-17.28, diluted EPS of $-17.28, free cash flow per share of $-6.01, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 152.38% year-over-year and EPS growth of 10.85% year-over-year. On the balance sheet, it maintains a current ratio of 0.60x, a quick ratio of 0.56x, working capital of $-5.61M, a debt-to-equity ratio of 1.08x, a debt ratio of 0.52, an interest coverage ratio of -31.46x, free cash flow of $-10.76M (TTM), and net debt of $-7.06M. Figures sourced from SEC EDGAR.
- Market Cap
- $18.35M
- P/E TTM
- -0.59x
- EPS TTM
- $-17.28
- P/B TTM
- 0.99x
- ROE TTM
- -140.09%
- ROA TTM
- -69.16%
- Debt To Equity
- 1.08x
- Free Cash Flow TTM
- $-10.76M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Akari Therapeutics Plc in?
Akari Therapeutics Plc (AKTX) operates in the Pharmaceutical Preparations industry.
What exchange does AKTX trade on?
Akari Therapeutics Plc (AKTX) trades on the Nasdaq.
Where is Akari Therapeutics Plc incorporated?
Akari Therapeutics Plc is incorporated in United Kingdom.
When was Akari Therapeutics Plc (AKTX)'s most recent SEC filing?
Akari Therapeutics Plc (AKTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is AKTX's market cap?
Akari Therapeutics Plc (AKTX) has a market capitalization of $18.35M as of 2026-06-30.
What is AKTX's EPS (earnings per share)?
Akari Therapeutics Plc (AKTX)'s trailing twelve month EPS is $-17.28 as of 2026-06-30.
What is AKTX's ROE (return on equity)?
Akari Therapeutics Plc (AKTX)'s trailing twelve month Return on Equity (ROE) is -140.09% as of 2026-06-30.
What is AKTX's ROA (return on assets)?
Akari Therapeutics Plc (AKTX)'s trailing twelve month Return on Assets (ROA) is -69.16% as of 2026-06-30.
What is AKTX's ROIC (return on invested capital)?
Akari Therapeutics Plc (AKTX)'s trailing twelve month Return on Invested Capital (ROIC) is -175.85% as of 2026-06-30.
What is AKTX's EV/EBITDA?
Akari Therapeutics Plc (AKTX)'s trailing twelve month EV/EBITDA is -0.36x as of 2026-06-30.